Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug : Drug Combination with Ibrutinib

PURPOSE: Pan-class I/II histone deacetylase (HDAC) inhibitors are effective treatments for select lymphomas. Isoform-selective HDAC inhibitors are emerging as potentially more targeted agents. ACY-1215 (ricolinostat) is a first in class selective HDAC6 inhibitor. To better understand the discrete fu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Amengual, Jennifer E., Prabhu, Sathyen A., Lombardo, Maximilian, Zullo, Kelly, Johannet, Paul M., Gonzalez, Yulissa, Scotto, Luigi, Serrano, Xavier Jirau, Wei, Ying, Duong, Jimmy, Nandakumar, Renu, Cremers, Serge, Verma, Akanksha, Elemento, Olivier, O'Connor, Owen A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5474138/
https://ncbi.nlm.nih.gov/pubmed/27993968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados